Rare Disease Leader Chooses Toronto to Support Growth Plans
TORONTO, Oct. 2, 2017 /CNW/ - Shire Pharma Canada ULC (Shire Canada) celebrated their official opening of their new offices in downtown Toronto last Thursday, marking their continued commitment to invest in Canada. The new location is ideally situated in Canada's largest biotech cluster, offering a range of opportunities for collaboration and partnership.
"Our new Toronto location provides access to a thriving life sciences sector and is a great base from which to attract talent for the organization," said Eric Tse, General Manager for Shire Canada. "It will also serve to promote closer collaboration and strengthen relationships with key external stakeholders in academic research, clinical practice, patient advocacy and medical innovation."
The Toronto region is home to more than 11,000 principal researchers and technicians, 37 research institutes, eight universities and colleges, world class research hospitals and numerous private sector research facilities.
"I am delighted that Shire Canada has chosen Toronto as its new Canadian base," said Reza Moridi, Ontario Minister of Research, Innovation and Science. "Shire Canada has shown it recognizes Ontario's talented workforce as a source of competitive advantage. We are pleased to welcome Shire into our innovative life sciences community."
Founded more than 30 years ago, Shire has long believed that they have a unique opportunity to champion the underserved patient communities. It is estimated that one in 12 Canadians has a rare disorder. Most rare diseases are genetic and pose a significant medical, economic and societal burden for patients, communities and the health care system. As many as 7,000 rare diseases have been identified yet few than 5% of them have treatments available for patients who need them. With a rich heritage of treating rare diseases and specialised conditions, Shire offers unique expertise to meet the high unmet need of these groups.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Haematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Shire Pharma Canada ULC is a subsidiary of Shire. Our Canadian office is located in Toronto, Ontario.
SOURCE Shire Pharma Canada ULC
For further information: Media - Shire: Amanda Jacobs, [email protected], +1 647 798 2231